Resumen

CARDENAS DIAZ, Taimi et al. Use of Bevacizumab in corneal neovascularization. Rev Cubana Oftalmol [online]. 2012, vol.25, n.2, pp. 330-335. ISSN 0864-2176.

Neovascularization of the cornea is a cause of loss of transparency of the same and is also a risk factor for secondary rejection corneal transplants. Bevacizumab is a humanized monoclonal antibody that selectively blocks the formation of the VEGF cascade and, with this, decreases the formation of blood vessels. Three cases with corneal neovascularization from different causes were presented, which were given three doses of 2.5 mg subconjunctival bevacizumab once a month. A partial regression of corneal neovascularization was observed in the treated eyes, being more visible in the patient with a history of corneal burn.

Palabras clave : corneal neovascularization; antiangiogenic; bevacizumab; avastin.

        · resumen en Español     · texto en Español     · Español ( pdf )